Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address ...

Short-chain fatty acids (SCFAs) like propionate and butyrate are critical byproducts of dietary fiber digestion. These molecules do more than fuel the body—they directly influence gene expression and ...

Biodexa Strengthens Management Team Appointment of Dr Gary A. Shangold as Chief Medical Officer Biodexa Pharmaceuticals PLC ("Biodexa" or "the Company"), (Nasdaq: BDRX), a clinical ...

Biodexa Strengthens Management TeamAppointment of Dr Gary A. Shangold as Chief Medical OfficerBiodexa Pharmaceuticals PLC ...

Aromatase is an enzyme that converts testosterone to estradiol, a type of estrogen. One study found that taking an estrogen blocker called an aromatase inhibitor while on testosterone therapy reduced ...

GAITHERSBURG, Md. - Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH), a specialty pharmaceutical company with a current market capitalization of $3.08 million, has reached a milestone in its Phase ...

Ph.D. Program in Medical Neuroscience, College of Medical Science and Technology, Taipei Medical University and National Health Research Institutes, Taipei 110, Taiwan International Master Program in ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Histone deacetylase inhibitor. Givinostat (Duvyzat) is the first non-steroid drug approved to treat people with all genetic variations of DMD. It delays the disease's progression by targeting an ...

Laboratory for Drug Design and Synthesis, Department of Pharmaceutical Sciences and Natural Products, School of Pharmaceutical Sciences, Central University of Punjab, Bathinda 151 401, India ...

REC-2282. Also anticipated to produce data before 2024 closes out is REC-2282, an oral, small-molecule, CNS-penetrant histone deacetylase inhibitor undergoing evaluation in the treatment of ...